Taran K. Peculiarities of metabolic syndrome development under condition of estrogen deficiency and its pharmacological correction (experimental research).

The object of study: metabolic and functional disorders induced by insulin resistance syndrome in rats with estrogen deficiency. The aim of the study: to identify metabolic and functional disorders induces by insulin resistance syndrome in estrogen deficiency and to ground the efficacy of novel 17в-estradiol derivative with antioxidant activity use for postmenopausal metabolic syndrome correction. The methods of the study: biochemical, biophysical, physiological, immunological, pharmacological, statistics. The role of endogenous and exogenous 17в-estradiol in development of main metabolic syndrome compounds of different genesis was established for the first time. It was revealed that treatment with compound PE0607 ameliorates insulin resistance and abdominal obesity, improves dyslipidemia, suppresses oxidative stress, prevents proinflammatory and protrombotic states, increases nitric oxide production, improves bioenergetics processes and suppresses oxidative stress in cardiomyocyte's mitochondria without proliferative processes stimulation in uterus in ovariectomized rats with metabolic syndrome. The established pharmacological properties of compound PE0607 substantiate its use as the potential cardioprotective agent for the postmenopausal metabolic syndrome prevention. The sphere of application: endocrinology, cardiology, pharmacy.